Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers find more uses for immune system's 'Swiss army knife'

Research

Oxford University research has found that a little-studied and relatively unknown part of the human immune system could be twice as important as previously thought.

© Liya Graphics - Shutterstock

Image courtesy of Shutterstock

Mucosal Associated Invariant T-cells (MAIT cells) were first identified in 1993 but largely ignored until recently. Australian researchers recently found that they had an important role in fighting bacterial infections. Now, the Oxford team, led by Professor Paul Klenerman, say that they also fight viruses. Their results are in the journal Nature Communications.

Researcher Bonnie van Wilgenburg said: 'MAIT cells are unlike any other part of the immune system because they are multipurpose, rather than responding to particular pathogens – the various bacteria, viruses and other microorganism that can cause disease.'

Read more

Similar stories

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.

RECOVERY trial Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Major new study could help protect millions of people with type 2 diabetes from cardiovascular disease

A new study led by the Nuffield Department of Population Health at the University of Oxford will research whether a daily tablet could help protect the millions of people worldwide with type 2 diabetes from developing cardiovascular disease.

Scientists make DNA breakthrough which could identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine at Oxford University have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.